

NON-OPIOID EXPAREL®

(bupivacaine liposome injectable suspension)


DENTAL AND ORAL SURGERY RESOURCES FOR EXPAREL



THE FIRST AND ONLY FDA-APPROVED LONG-ACTING
LOCAL ANALGESIC FOR AGES 6 AND ABOVE¹



MORE THAN **8 MILLION ADULT PATIENTS** HAVE RECEIVED EXPAREL SINCE 2012²



Informative resources are available for your review on
www.exparel.com, including procedure videos and case reports

CLICK ON IMAGES BELOW
TO LEARN MORE ▼

EXPAREL in Pediatrics

Learn more about the safety
and dosing of EXPAREL in
patients 6 to 17 years old.



Administrative Case Reports and Videos

Administration Case Report With EXPAREL	
Procedure Name	Third Molar Extraction
Patient Name	John D. Smith, MD
Age	17
Sex	Male
Procedure Date	10/15/2015
Procedure Location	Oral Surgery
Procedure Type	Removal of impacted tooth - partially bony
Procedure Duration	15 minutes
Procedure Notes	3 x 100mg EXPAREL (300mg total) infiltrated into the surgical site.



Third Molar Extraction

Administration Case Report With EXPAREL	
Procedure Name	Full maxillary reconstruction infiltration
Patient Name	John D. Smith, MD
Age	35
Sex	Male
Procedure Date	10/15/2015
Procedure Location	Oral Surgery
Procedure Type	Removal of impacted tooth - partially bony
Procedure Duration	15 minutes
Procedure Notes	3 x 100mg EXPAREL (300mg total) infiltrated into the surgical site.




Full maxillary
reconstruction
infiltration

Bilateral
temporomandibular
joint arthroplasty*

Patient and Care Team Resources

Additional tools such as patient wristbands, syringe
stickers, and patient education materials.



Patient Wristband



OMFS Syringe Stickers

OMFS=oral maxillofacial surgery.


*A case report is also available through the link.

†Content for informational purposes only. Pacira cannot guarantee
successful reimbursement for EXPAREL from the use of provided
resources. Reimbursement criteria will vary by payer.

Surgeon Selector

A searchable database that allows
patients to find health care providers,
like you.

Register for Surgeon Selector to set
your facility apart.



Reimbursement



Reimbursement codes for EXPAREL
and related billing guidance are
provided to ensure you have timely
information.† To contact Pacira's
dedicated reimbursement specialists:



Email reimbursement@pacira.com




Call the reimbursement helpline at
855-793-9727



Ordering EXPAREL

Contact your wholesaler or order directly
from Pacira.



Continue to View Tools for Your Practice

Please see Important Safety Information on next page. [CLICK HERE](#) for full Prescribing Information.

Tools for Your Practice

A tool kit is available to help you spread awareness and educate patients and the community about your non-opioid approach for managing postsurgical pain.

Differentiate your practice
by highlighting your
opioid-minimizing efforts

**Communicate with your
patients** about your approach to
postsurgical pain management and
reducing the need for opioids

**Explain the role
EXPAREL plays** in
accomplishing
these goals



Indication

EXPAREL® (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in patients aged 6 years and older to produce postsurgical local analgesia and in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritis, and tachycardia.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for interscalene brachial plexus nerve block, and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block**, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Full Prescribing Information is also available at www.EXPAREL.com.

References: 1. Pacira BioSciences. Pacira announces FDA approval of supplemental new drug application for EXPAREL® (bupivacaine liposome injectable suspension) in pediatric patients [press release]. Pacira website. <https://investor.pacira.com/news-releases/news-release-details/pacira-announces-fda-approval-supplemental-new-drug-0>. Published March 22, 2021. Accessed May 12, 2021. 2. Data on file. 6450. Parsippany, NJ: Pacira BioSciences, Inc.; January 2021.